LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.69 -3.1

Buy Sell

Overview

Share price change

24h

Current

Min

4.57

Max

4.88

Key metrics
By Trading Economics
Income	31M -172M
Sales	4.4M 19M
Profit margin	-899.843
Employees	800
EBITDA	44M -148M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+24.74% upside

Market Stats
By TradingEconomics
Market Cap	-432M 2.1B
Previous open	7.79
Previous close	4.69

News Sentiment

By Acuity

50%

185 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 wrz 2025, 17:03 UTC

Major Market Movers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 wrz 2025, 16:49 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 wrz 2025, 16:11 UTC

Major Market Movers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 wrz 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 wrz 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 wrz 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 wrz 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 wrz 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 wrz 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 wrz 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 20:25 UTC

Earnings

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 wrz 2025, 20:24 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 wrz 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 wrz 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 wrz 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 wrz 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 wrz 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 wrz 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 wrz 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 wrz 2025, 16:53 UTC

Earnings

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 wrz 2025, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 16:15 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 wrz 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 wrz 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

24.74% upside

12 Months Forecast

Average 5.95 USD 24.74%

High 8 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

185 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.